Enlivex Therapeutics (ENLV) Competitors $0.86 0.00 (-0.35%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. VIGL, BMEA, ADVM, THTX, ZURA, GNLX, ENTX, AVTE, ADAG, and TCRXShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Vigil Neuroscience (VIGL), Biomea Fusion (BMEA), Adverum Biotechnologies (ADVM), Theratechnologies (THTX), Zura Bio (ZURA), Genelux (GNLX), Entera Bio (ENTX), Aerovate Therapeutics (AVTE), Adagene (ADAG), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Vigil Neuroscience Biomea Fusion Adverum Biotechnologies Theratechnologies Zura Bio Genelux Entera Bio Aerovate Therapeutics Adagene TScan Therapeutics Enlivex Therapeutics (NASDAQ:ENLV) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Which has stronger valuation & earnings, ENLV or VIGL? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$0.73-1.17Vigil NeuroscienceN/AN/A-$82.64M-$2.06-0.81 Do analysts recommend ENLV or VIGL? Enlivex Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 1,066.86%. Vigil Neuroscience has a consensus target price of $16.25, indicating a potential upside of 878.92%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Vigil Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Vigil Neuroscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ENLV or VIGL? In the previous week, Enlivex Therapeutics had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 1 mentions for Enlivex Therapeutics and 0 mentions for Vigil Neuroscience. Vigil Neuroscience's average media sentiment score of 1.89 beat Enlivex Therapeutics' score of 1.44 indicating that Vigil Neuroscience is being referred to more favorably in the news media. Company Overall Sentiment Enlivex Therapeutics Positive Vigil Neuroscience Very Positive Is ENLV or VIGL more profitable? Enlivex Therapeutics' return on equity of -67.57% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -67.57% -58.45% Vigil Neuroscience N/A -83.89%-65.34% Do institutionals & insiders have more ownership in ENLV or VIGL? 1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 18.0% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in ENLV or VIGL? Enlivex Therapeutics received 26 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 84.62% of users gave Vigil Neuroscience an outperform vote while only 80.82% of users gave Enlivex Therapeutics an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes5980.82% Underperform Votes1419.18%Vigil NeuroscienceOutperform Votes3384.62% Underperform Votes615.38% Which has more volatility and risk, ENLV or VIGL? Enlivex Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. SummaryEnlivex Therapeutics beats Vigil Neuroscience on 9 of the 16 factors compared between the two stocks. Remove Ads Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.35M$6.46B$5.30B$7.37BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-0.876.8221.6917.76Price / SalesN/A227.25377.9494.24Price / CashN/A65.6738.1534.64Price / Book0.535.856.413.98Net Income-$29.07M$142.26M$3.20B$247.41M7 Day Performance-5.82%7.31%4.61%4.22%1 Month Performance-25.48%-14.38%-9.97%-7.89%1 Year Performance-42.09%-9.85%10.75%1.25% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3345 of 5 stars$0.86-0.3%$10.00+1,066.9%-40.7%$18.35MN/A-0.8770Short Interest ↓Positive NewsGap UpVIGLVigil Neuroscience3.1996 of 5 stars$1.54-1.3%$16.25+955.2%-50.2%$75.65MN/A-0.7540Gap DownBMEABiomea Fusion2.6652 of 5 stars$2.01-5.2%$23.91+1,089.5%-86.7%$75.52MN/A-0.5050Positive NewsADVMAdverum Biotechnologies3.9138 of 5 stars$3.63-6.0%$27.83+666.8%-74.3%$75.51M$1M-0.61190Earnings ReportAnalyst ForecastNews CoverageTHTXTheratechnologiesN/A$1.64+10.8%N/A+100.8%$75.41M$85.87M-16.40140Short Interest ↑Analyst RevisionNews CoverageZURAZura Bio1.8418 of 5 stars$1.15+11.7%$14.67+1,175.4%-62.2%$75.09MN/A-2.173GNLXGenelux1.0372 of 5 stars$2.16-9.6%$18.25+744.9%-27.0%$74.75M$8,000.00-2.2710ENTXEntera Bio2.3602 of 5 stars$1.63+1.9%$10.00+513.5%-23.1%$74.04M$181,000.00-6.2720Positive NewsGap DownAVTEAerovate Therapeutics0.697 of 5 stars$2.52+1.2%$2.25-10.7%-88.7%$73.04MN/A-0.8420ADAGAdagene2.1607 of 5 stars$1.54-2.6%$8.00+419.5%-39.2%$72.55M$103,204.000.00260Short Interest ↑Positive NewsGap UpTCRXTScan Therapeutics2.8711 of 5 stars$1.26+14.5%$9.33+640.7%-81.8%$71.31M$2.82M-1.19100High Trading Volume Remove Ads Related Companies and Tools Related Companies VIGL Competitors BMEA Competitors ADVM Competitors THTX Competitors ZURA Competitors GNLX Competitors ENTX Competitors AVTE Competitors ADAG Competitors TCRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENLV Stock Free ENLV Stock Alerts